Pfizer's Cannabinoid-Related Biotech Company Arena's Q4 Net Loss Grows 27% YoY

Loading...
Loading...

Arena Pharmaceuticals, Inc. ARNA revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021.

Q4 Finanical HIghlights

  • Net loss for the fourth quarter was $155.6 million compared to a net loss of $122.2 million for the same period in 2020
  • Basic and diluted net loss per share for the fourth quarter was $2.54 compared to basic and diluted net loss per share of $2.10 for the same period in 2020
  • Research and development (R&D) expenses for the fourth quarter totaled $110.3 million compared to $100.4 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as well as an increase in personnel expenses to support our clinical programs.
  • Selling, general and administrative (SG&A) expenses for the fourth quarter totaled $34.5 million, compared to $34.9 million in the same period in 2020.
  • Cash, cash equivalents and marketable securities were $700 million at December 31, 2021 as compared to $1.1 billion at December 31, 2020

Full Year 2021 Financial Results

  • Revenues totaled $100,000
  • Net loss was $616.4 million, or $10.14 per share
  • Research and development expenses totaled $419.5 million, including $33.5 million related to non-cash share-based compensation
  • Selling, general and administrative expenses totaled $126.2 million, including $36.9 million related to non-cash share-based compensation
  • Key Program & Corporate Updates

  • In December pharmaceutical giant Pfizer Inc. PFE and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena
  • In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn’s disease
  • In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud’s phenomenon secondary to systemic sclerosis
  • Phase 3 ELEVATE program for etrasimod in ulcerative colitis remains on track for topline data readout in Q1 2022

About Arena Pharmaceuticals

 

Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsMarkets

Benzinga Cannabis Conferences are coming to Los Angeles

Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape, and shape the evolving markets in California and beyond. Don’t miss this chance to be at the forefront of the cannabis industry’s growth and innovation! Join now


Loading...